{"id":1001086,"date":"2026-09-08T07:39:24","date_gmt":"2026-09-08T11:39:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/"},"modified":"2026-09-08T07:39:24","modified_gmt":"2026-09-08T11:39:24","slug":"briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/","title":{"rendered":"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:left\">\n          <strong><br \/>\n            <em>Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK)<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:left\">\n          <strong><br \/>\n            <em>BriaCell Phase 3 trial <a href=\"https:\/\/feeds.issuerdirect.com\/news-release.html?newsid=8024473194415951&amp;symbol=BCTX\" rel=\"nofollow\" target=\"_blank\">featured in Nature Medicine<\/a> as \u201cEleven clinical trials that will shape medicine in 2026\u201d<\/p>\n<p><\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, Sept.  08, 2026  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell\u2019s ongoing pivotal Phase 3 study of Bria-IMT\u2122 plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4_3kusS5Lb-rxMjXYddVnHzd01lTL2h6Acau3V3UrB6mpb8wNxX5wzY31k107vxsBAlCxSglA0yWA6RvzmzM72vqq-63L32WTh3-VRJxOay_ddkrURA84LDi6s6sTQX6\" rel=\"nofollow\" target=\"_blank\"><strong>NCT06072612<\/strong><\/a>).<\/p>\n<p align=\"justify\">BriaCell\u2019s Phase 3 study now has more than 80 active clinical sites across 15 states, including Penn Medicine\u2019s Abramson Cancer Center, Mayo Clinic, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology\/Oncology Associates, New York Cancer &amp; Blood Specialists, Northwestern University, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Texas Oncology-Baylor Charles A. Sammons Cancer Center, and University of Arizona.<\/p>\n<p align=\"justify\">\u201cWe are pleased to welcome MSK as a clinical site in BriaCell\u2019s Phase 3 study,\u201d stated Dr. William V. Williams, BriaCell\u2019s President &amp; CEO. \u201cMSK is one of the world\u2019s leading cancer centers, and its participation expands patient access to the Bria-IMT regimen as we continue advancing a potential new therapeutic approach for heavily pretreated patients.\u201d<\/p>\n<p align=\"justify\">\u201cWe are pleased that MSK is now enrolling patients in BriaCell\u2019s pivotal Phase 3 study evaluating Bria-IMT for advanced breast cancer in patients with limited therapeutic options. We look forward to collaborating with BriaCell,\u201d\u00a0commented Phaedon Zavras, MD, the MSK Breast Medical Oncologist and Assistant Attending Physician who is serving as principal investigator for the MSK study site.<\/p>\n<p align=\"justify\">BriaCell\u2019s pivotal Phase 3 clinical study is evaluating BriaCell\u2019s lead clinical candidate, Bria-IMT in combination with an immune check point inhibitor (CPI), compared with physician\u2019s choice of treatment in\u00a0<strong>a<\/strong>dvanced metastatic\u00a0<strong>b<\/strong>reast\u00a0<strong>c<\/strong>ancer (the Bria-ABC study).<\/p>\n<p align=\"justify\">The study\u2019s primary endpoint is overall survival (OS). An interim analysis is planned after 144 deaths have occurred, comparing OS in patients treated with the Bria-IMT combination regimen versus those treated with physician\u2019s choice. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1WaMQOUX4sEfZKYiuu-230B6LxfNKXeIVl-NJRLc7zNqyGT48T9I4gmboFiR0-HthDdhJxp9KI0iKA8MRjmZmUUSa4XdXQTCJdsn8IiRgZWVkifZj-g9wt-1Ubsy53flZJdkuvYixGXpf5OCjaGBQKrK6R_tsZ1d8ZhAEdTgqduK8TuSN9z68JWOxqZ2kvq3TFFB1pum3D1Co9lja3EDf_TUzhgN00srOkJ91ccU67Qffouplyu-jxTaQgBfAlNM8ZGUbj8hcDVH8U1eEIxcrFxFoxTE22QhG_0Wz5mOXi4mQoO6vmK26eISSRzXt9HaoyL-f6f2TWc3GvFXxbfB7YfnKyXpJW6u7VCJELaUdLKTaSoOkmMUY9IBPtsBwkdQ\" rel=\"nofollow\" target=\"_blank\">BriaCell recently received a positive recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the Phase 3 Study in metastatic breast cancer<\/a>.\u00a0At ASCO 2026, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1WaMQOUX4sEfZKYiuu-23-odaWxHpK9NveUT3fgPutiXAKtWNb96BM5Ai55r-ek5P6utW9Yu1LXeM37FdGz56se_at6kFc9j6IXscgfpJ42vyA-USxMwGTU64LJgF6T79wa8e2Q81JG1Wqb-fYrKoxXt5xJA3vtdD517QAOjl89O6EUltrcI1U2hIXbpVgZMU-IbtwSXdj4uIpqpaTdzJ4FP_ADurUDdyz4hFLlr4kqGqH-Gv4Rnmf-HW7S5qRM4VuO4xjibXfv0Y3s16lbzTc0IGPK1CcEtFsGEesLyioUKIwRm4p_ZhHT0Xp5HASqjT8Rje7g3oTFu3LBYVpNYltuQRbIV_hzXlnv8WSsqjqFJ7zbAUFhpyMjJs8MBqwO_\" rel=\"nofollow\" target=\"_blank\">BriaCell also announced positive Phase 2 survival data in a similar metastatic breast cancer patient population treated with the same Bria-IMT combination regimen<\/a>. The Bria-IMT combination regimen has received FDA Fast Track designation.<\/p>\n<p align=\"justify\">For additional information on BriaCell\u2019s pivotal Phase 3 study of Bria-IMT please visit ClinicalTrials.gov\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4_3kusS5Lb-rxMjXYddVnCbdKEI2ThllZTj7Sn6AWynztYSuHJkDuXeKUIMdz0jiMvFUqHhKWrheBgKj9XMZjUKqfGUt9SldZPt7OuuAVbL1snI-ctNAB9bOxOEo9ZsT\" rel=\"nofollow\" target=\"_blank\"><strong>NCT06072612<\/strong><\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Memorial Sloan Kettering Cancer Center (MSK) has institutional financial interests related to BriaCell.<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8GTDi54VegHyfgjgMa1XKLCLEndTys1SwSThqmgDHoSvxqP8r765XwTiohNyOGgnjAPSrKEZXxPqLb3az_V9GZW7HNGjO-TD8SkU89b8Lm8=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those regarding BriaCell\u2019s ongoing Phase 3 study of Bria-IMT in metastatic breast cancer, the enrollment of MSK and expansion of clinical trial sites, the potential therapeutic benefits of the Bria-IMT regimen, and the recognition of the Phase 3 study by <em>Nature Medicine<\/em> as one of the clinical trials expected to shape medicine in 2026,are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company\u2019s profiles on SEDAR+ at <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wot-qMLy-2yEwMfCYXBf_C7dvTRXoku8kQapm7Tyh_XqMa785fXszT7THUALDQe4UQ0GUZj0TieAwucQA52AcpG7RCoCrBtMP7Y32RFe8I4=\" rel=\"nofollow\" target=\"_blank\">www.sedarplus.ca<\/a><\/strong>and on EDGAR at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wot-qMLy-2yEwMfCYXBf_L3x8D7vh7qSwqlTC4542a-g6lQDApHhRZoDIFNPoNcsGanrM7s3LAClZXMMFhxnoQ==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"left\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7kpLD_5-EEALRyspGmB3a23N3SYlyeZ2_xejRkekZWZro8Kf_AWEcX3-eR1epwg3OzerPR6gxvmvg6PNpwcloJUSy4xR3tfuzORI_0m8MKM=\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a>\u00a0<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UV5ON8aGV9sdM75zkQ-TpPgTzT3nWeK40RSgYvHcDeIs7bGub1dLPHqv_Plt8qKibaZa8jLGIsrto5ffk20PVOFlu1fjPruiD7nXrAy0Ias=\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjFkYmZlZDQtZjQ5Zi00ODY4LTg2MjktNTUyNjhlYzBiM2M0LTExMDIyMjktMjAyNi0wOS0wOC1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK) BriaCell Phase 3 trial featured in Nature Medicine as \u201cEleven clinical trials that will shape medicine in 2026\u201d PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell\u2019s ongoing pivotal Phase 3 study of Bria-IMT\u2122 plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612). BriaCell\u2019s Phase 3 study now has more than 80 active clinical sites across 15 states, including Penn Medicine\u2019s Abramson Cancer Center, Mayo Clinic, DHR Health Oncology Institute, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1001086","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK) BriaCell Phase 3 trial featured in Nature Medicine as \u201cEleven clinical trials that will shape medicine in 2026\u201d PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell\u2019s ongoing pivotal Phase 3 study of Bria-IMT\u2122 plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612). BriaCell\u2019s Phase 3 study now has more than 80 active clinical sites across 15 states, including Penn Medicine\u2019s Abramson Cancer Center, Mayo Clinic, DHR Health Oncology Institute, &hellip; Continue reading &quot;BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T11:39:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center\",\"datePublished\":\"2026-09-08T11:39:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/\"},\"wordCount\":827,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/\",\"name\":\"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=\",\"datePublished\":\"2026-09-08T11:39:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center - Market Newsdesk","og_description":"Now Enrolling Patients at Memorial Sloan Kettering Cancer Center (MSK) BriaCell Phase 3 trial featured in Nature Medicine as \u201cEleven clinical trials that will shape medicine in 2026\u201d PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell\u2019s ongoing pivotal Phase 3 study of Bria-IMT\u2122 plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612). BriaCell\u2019s Phase 3 study now has more than 80 active clinical sites across 15 states, including Penn Medicine\u2019s Abramson Cancer Center, Mayo Clinic, DHR Health Oncology Institute, &hellip; Continue reading \"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-08T11:39:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center","datePublished":"2026-09-08T11:39:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/"},"wordCount":827,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/","name":"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=","datePublished":"2026-09-08T11:39:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTg2NyM3ODE5MzA3IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacells-pivotal-phase-3-metastatic-breast-cancer-study-expands-to-leading-cancer-center\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell\u2019s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1001086"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001086\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1001086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1001086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1001086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}